A Retrospective Real-World Study Based on RATIONALE-307
Recruiting · NCT07478809 · Observational (researchers observe without assigning treatment) · Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
View the official record on ClinicalTrials.gov →Interventions studied
No intervention
What this trial is about
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Exclusion criteria
- Patients who had a documented death before study completion in the RATIONALE-307 trial
Where it is running
1 location listed.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College - Beijing, China